Abstract In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breast cancer patients participating in the GeparQuattro trial. This study incorporated NT approaches and additional trastuzumab treatment for all patients with HER2-positive tumors. Human epidermal growth factor receptor 2 serum levels were measured by enzyme-linked immunosorbent assay (ELISA) before initiation of NT and after NT (pre-surgery) in a HER2-positive (n = 90) and a HER2-negative patient cohort (n = 85). Median pre-chemotherapy sHER2 levels were higher in patients with positive HER2 status of the primary tumor than in patients with negative HER2 status (14.9 ng/ml vs. 7.7 ng/ml, P \ 0.001). A pre-chemotherapy sHER2 cut-off level of 10 ng/ml had the best sensitivity and specificity in discriminating between HER2-positive and HER2-negative primary tumors. In HER2-positive patients, we found a significant positive 
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Introduction
Neoadjuvant therapy (NT) strategies allow the assessment of therapeutic efficacy of chemotherapy-and novel-targeted approaches in breast cancer patients without long follow-up periods which are required in the adjuvant setting. The German Breast Group and the AGO study group have conducted successful clinical trials in the neoadjuvant setting over the last years [1] [2] [3] . The study GeparQuattro was a phase III trial program that incorporated different NT approaches for primary breast cancer (epirubicin/cyclophosphamide (EC) prior to randomization to either docetaxel alone, docetaxel in combination with capecitabine or docetaxel followed by capecitabine) and additional trastuzumab treatment for human epidermal growth factor receptor 2 (HER2) positive patients [4, 5] . This setting offered an opportunity for translational research projects examining biomarkers that should allow improving the knowledge of mechanisms underlying modern treatment strategies.
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-20% of primary breast cancers. Breast tumors that exhibit HER2 protein overexpression or gene amplification are more aggressive and more likely to recur [6] [7] [8] . The HER2 protein is a 185-kDA transmembrane tyrosine kinase receptor with three defined domains: the intracellular tyrosine kinase portion, a short transmembrane portion, and the extracellular domain (ECD). This 105-kDa ECD (HER2 serum, sHER2) can be cleaved from the surface by metalloproteases and detected in the peripheral blood [9] . It was reported that trastuzumab inhibits HER2 ECD cleavage and that the remaining cleaved HER2 receptor is constitutively activated [10, 11] , suggesting that the presence of sHER2 also reflects a biologic process leading to a more aggressive tumor behavior [12] . Elevated levels of sHER2 are observed in patients with primary breast cancer [13] or metastatic breast cancer [14, 15] .
Trastuzumab, a monoclonal antibody directed against HER2, has become a standard treatment in HER2-positive breast cancer patients and has also increased remission rates after NT [16] . A number of new treatment approaches directed against HER2 are currently examined in clinical trials, but the optimal use of these compounds is still unclear.
Also, the increasing use of NT in patients with primary breast cancer requires the identification of predictive markers of pathologic response which is a surrogate marker of survival [17, 18] .
The role of sHER2 in the neoadjuvant setting with the use of HER2-targeted therapies is unclear. Therefore, the purpose of this study was to determine sHER2 levels in patients with non-metastatic breast cancer before NT and after NT prior to surgery. We evaluated the potential utility of sHER2 levels for predicting response to treatment, in particular in patients treated with trastuzumab-based regimens, and compared results of a HER2-positive cohort with a HER2-negative patient cohort.
Materials and methods

The clinical study GeparQuattro
Patients with either large operable or locally advanced tumors; tumors with negative hormone receptor status; or receptor positive tumors but clinically node-positive disease were recruited to receive preoperatively four cycles of EC (90 mg/m 2 /600 mg/m 2 ) and to be then randomized to either four cycles of docetaxel (T) (100 mg/m 2 ) or four cycles of T ? capecitabine (X) (75 mg/m 2 /1800 mg/m 2 ) (TX) or four cycles of T (75 mg/m 2 ) followed by four cycles of X (1800 mg/m 2 ) (T ? X). Patients with HER2-positive tumors received trastuzumab (6 mg/kg i.v. every 3 weeks) concomitantly to cytotoxic treatment, starting with a loading dose of 8 mg/kg i.v. on day 1 of the first ECcycle. Primary objectives were to assess the effect of X and to assess the effect of therapy duration. Primary endpoint of the study was pathological complete remission (pCR). Secondary endpoint was breast-conserving therapy. Trastuzumab was given to patients with HER2-positive tumors.
HER2 positivity was defined as IHC 3? or fluorescence in situ hybridization (FISH) positive of the primary tumor. The standardized immunohistochemistry assay HercepTest Ò by DakoCytomation was mandatory and all IHC 2? cases had to be centrally analyzed by FISH assay in one of five German reference centers. The trial registration number (at Clinicaltrials.gov) is NCT00288002.
Inclusion criteria for the translational sub-protocol and ethical considerations Full blood samples before and after chemotherapy were collected for patients eligible for the GeparQuattro study in the participating centers. Samples were stored at -20°C and shipped on dry ice. All patients gave informed consent to provide a prespecified amount of extra blood before entering the GeparQuattro study with the informed consent form. Participation on the clinical trial was still possible if a patient did not agree to provide extra blood samples. Patients were not informed about the laboratory results due to their experimental character. The clinical treatment study as well as the translational research project described here were approved by the central ethics committee at the Fig. 1 Human epidermal growth factor receptor 2 serum levels before initiation of chemotherapy in HER2-positive and HER2-negative patients. Human epidermal growth factor receptor 2 serum levels are significantly higher in HER2-positive patients than in HER2-negative patients (P \ 0.001)
Interventions
Serum samples were collected in the study centers and send to the German Breast Group. Correct labeling was checked and 175 serum samples (90 of HER2-positive and 85 of HER2-negative patients) were forwarded to the Department of Gynecology, University Medical Center HamburgEppendorf. Medical records were stored in a central database at the GBG and the patient identifiers were kept confidential so the assay was performed blinded for the clinical results. After serum determination, results were assigned to the medical records and double-checked. Detailed patient characteristics are listed in Table 1 .
Patients were randomly selected for inclusion in the study.
Since the availability of serum is not based upon tumor size (as it is for tissue), no relevant differences between the patient characteristics of the entire study and this subprotocol were observed (data not shown).
Enzyme-linked immunosorbent assay
Human epidermal growth factor receptor 2 serum was quantified by a commercially available ELISA (Siemens Healthcare Diagnostics, Inc., Tarrytown, NY, USA) as previously described [14] . The results were expressed in nanogramme per milliliter (ng/ml). Each sample, standard, and control was assayed in duplicate. Inter-and intra-assay coefficients of variation were less than 10%. A currently used cut off in the metastatic setting and also recommended by the manufacturer of the assay is 15 ng/ml [19, 20] . Therefore, serum levels above 15 ng/ml were regarded as elevated. Receiver operating characteristic (ROC) curve analysis was performed to determine an optimal sHER2 decline during NT corresponding to pCR. A decrease of sHER2 levels of more than 20 percent during NT was regarded as significant in the following analysis (sensitivity 75%, specificity 55%) [21] .
Statistical analysis
The statistical analysis was performed using SPSS 17.0 software (SPSS, Chicago, IL, USA). Each analysis was performed separately for the HER2-positive and HER2-negative patient cohort. Human epidermal growth factor receptor 2 serum levels were plotted against clinicopathological parameters by analysis of variance. The following groups were compared: tumor size less than 5 cm (pT1 ? 2) versus more than 5 cm (pT3 ? 4), G1/G2 versus G3; node-positive versus node-negative tumors; estrogen receptor positive versus negative, progesterone receptor positive versus negative; premenopausal versus postmenopausal, age \ 40 years versus C 40 years and HER2-positive versus HER2-negative primary tumors. Pathological complete remission was defined as no microscopic evidence of invasive tumor cells in all resected specimens of the breast and lymph nodes. The correlation between pCR and baseline variables was tested by logistic regression in the univariate and in the multivariate analysis. A two-tailed P value less than 0.05 was considered as statistically significant. The study was performed in accordance to the REMARK criteria published and discussed [22, 23] . End point for our analysis was the clinical end point of the study, the pCR, in correlation to absolute values and changes of sHER2 levels.
Results
A total of 175 patients were included in this analysis (Table 1) . There was no difference between HER2-positive and the 85 HER2-negative patients regarding median age, menopausal status, tumor size, nodal status, grading, and rate of breast conserving therapy. In the HER2-negative cohort, more patients were estrogen receptor positive (P = 0.02), progesterone receptor positive (P = 0.01), and less patients had a pCR (P \ 0.001). The comparison between HER2-positive and HER2-negative patients regarding clinicopathological parameters is listed in Table 2 .
Correlation between sHER2 levels and HER2 status Pre-chemotherapy sHER2 levels were determined in 167 patients. A total of 89 patients had HER2-positive and 78 patients HER2-negative primary tumors. Median pre-chemotherapy sHER2 levels were higher in patients with positive HER2 status than in patients with negative HER2 status (14.9 ng/ml vs. 7.7 ng/ml, P \ 0.001, Fig. 1 ). Significant differences between the patient cohorts are printed in bold Post-chemotherapy sHER2 levels (n = 164) were also associated with HER2 status (median 14.5 ng/ml in HER2-positive patients versus 8.2 ng/ml in HER2-negative patients, P \ 0.001). In HER2-positive patients, 44 patients (49%) had elevated pre-chemotherapy sHER2 levels (above 15 ng/ml), 41 patients (46%) had elevated post-chemotherapy sHER2 levels. In the HER2-negative cohort, only one patient (1%) had elevated pre-and post-chemotherapy sHER2 levels.
Pre-chemotherapy sHER2 levels above 15 ng/ml were associated with a positive HER2 status of the primary tumor in 44 of 89 patients (49%). Human epidermal growth factor receptor 2 serum levels below 15 ng/ml were associated with a negative HER2 status in 77 of 78 patients (99%). Thus, the specificity of the common sHER2 cut-off value of 15 ng/ml is high, with a low sensitivity in nonmetastatic patients. ROC-curve analysis revealed that a sHER2 cut-off level of 10 ng/ml had a higher sensitivity of 72%, a specificity of 85%, a positive predictive value of 85%, and a negative predictive value of 73% in discriminating between positive and negative HER2 status of primary tumors (Fig. 2) .
Change of sHER2 levels during chemotherapy
In HER2-positive patients, we determined a significant decline of sHER2 levels ([20%) during therapy in 49% of patients (n = 43). In HER2-negative patients, we found a significant decline only in 14% of the patients (n = 12). This difference between both groups was statistically significant (P = 0.039).
Regarding only those patients that started with elevated sHER2 levels above 15 ng/ml (n = 44), a significant decline of sHER2 levels ([20%) was seen in 32% of patients (n = 14). No difference in sHER2 level changes was seen between the group of patients with hormone receptor positive and hormone receptor negative tumors.
Correlation between sHER2 levels and clinicopathological parameters
In the HER2-positive cohort, we observed a positive correlation between nodal status and pre-chemotherapy sHER2 levels (P = 0.042). We observed no other correlations between clinicopathological parameters including age, menopausal status, tumor size, grading, histological type, estrogen, and progesterone receptor status and prechemotherapy sHER2 levels or post-chemotherapy sHER2 levels.
In the HER2-negative cohort, we observed a positive correlation between pre-chemotherapy sHER2 levels and menopausal status (P = 0.019) and between post-chemotherapy sHER2 levels and age (P = 0.017) and estrogen receptor status (P = 0.012).
We found no other statistically significant correlations between pre or post-chemotherapy sHER2 levels and the above mentioned parameters.
Pathological complete remission in relation to sHER2 levels and clinicopathological parameters In HER2-positive patients, we observed an association between pCR and negative hormone receptor status (P \ 0.001 for ER and P = 0.002 for PR), prechemotherapy sHER2 levels above 15 ng/ml (P = 0.045) and a decline of sHER2 levels ([20%) during NT (P = 0.02) in univariate analysis (Table 3) . Estrogen receptor status and decline of sHER2 levels ([20%) correlated with pCR in multivariate analysis adjusted for age, tumor size, nodal status, grading, progesterone receptor status, and prechemotherapy sHER2 levels (ER: OR = 7.46, 95% CI 2.73-20.39, P \ 0.001 and decline of sHER2 levels: OR = 3.29, 95% CI 1.001-10.89, P = 0.049), data not shown.
In the HER2-positive patient cohort, patients with pCR had higher sHER2 levels before chemotherapy than patients with no pCR (median 17.7 ng/ml vs. 13.1 ng/ml, P = 0.013). After the end of chemotherapy, sHER2 levels did not differ between patients with pCR or no pCR (median 15.2 ng/ml vs. 13.6 ng/ml, P = n.s.). HER2-positive patients with pCR had a median decrease of sHER2 levels of 26% in comparison to a median decrease of 10% in HER2-positive patients without pCR (P = 0.023).
In conclusion, HER2-positive patients with sHER2 levels above 15 ng/ml before therapy or patients with a minimum decline of sHER2 levels of 20% during therapy had a 60% higher probability of achieving a pCR than patients with sHER2 levels below 15 ng/ml or patients with a decline of less than 20% during therapy. In HER2-negative patients, only negative progesterone receptor status correlated with pCR in univariate (P = 0.001) as well as in multivariate analysis adjusted for the above mentioned parameters (OR = 16.2, 95% CI 1.41-186.85, P = 0.026), but no such differences were observed for patients with or without pCR with regard to sHER2 levels before and after chemotherapy. Detailed information about pCR and elevated sHER2 levels as well as change of sHER2 levels during NT in the HER2-positive and HER2-negative patient cohort is listed in Table 4 .
Breast-conserving therapy in relation to sHER2 levels and clinicopathological parameters In HER2-positive patients, breast-conserving therapy was associated with smaller tumor size (P \ 0.001) and decline of sHER2 levels (P = 0.035) in univariate analysis and only with smaller tumor size in multivariate analysis (OR = 0.17, 95% CI 0.06-0.48, P = 0.001, data not shown).
In HER2-negative patients, only smaller tumor size correlated with breast-conserving therapy in univarariate (P \ 0.001) and multivariate analysis (OR = 0.4, 95% CI 0.18-0.71, P = 0.003, data not shown), but no such correlation was observed for sHER2 levels or decline of serum levels.
Discussion
Pathologic complete response to induction chemotherapy is considered an important surrogate marker for long-term outcome of patients with primary breast cancer undergoing NT. Since no long follow up periods are required, this setting is used for the development of new treatment strategies and biomarker evaluation. To our knowledge, this study is the largest one to evaluate sHER2 levels in the context of trastuzumab treatment in the neoadjuvant setting. Furthermore, a HER2-negative cohort was selected as comparison group.
HER2 is a prominent therapeutic target in breast cancer and trastuzumab, a monoclonal antibody against this epidermal growth factor receptor, prolongs survival in the adjuvant and metastatic setting [24, 25] . The expression of HER2 in primary tumors is essential for trastuzumab treatment decisions of breast cancer patients [24] . However, the optimal use of trastuzumab and the various other drugs targeting HER2 that are currently in different phases of development are not clear yet. In the neoadjuvant setting, the effect of different therapies can be evaluated as the tumor is removed after treatment and tissue can be examined. In this context, different targeted therapy approaches are currently evaluated in clinical trials. The role of sHER2 in the adjuvant or neoadjuvant setting is still not well defined [26] .
The sHER2 ELISA system used in our study was approved by the US Food and Drug Administration in the year 2000. The currently approved cut-off for an elevated sHER2 is greater than 15 ng/ml, and circulating trastuzumab has been shown not to interfere with the assay [27] because the antibodies used recognize different and non-overlapping epitopes on the ECD than trastuzumab. Most published studies found no correlation between serum and tissue HER2 status among women with newly diagnosed breast cancer. Before initiation of NT, Köstler et al. [28] found the HER2 ELISA to have a sensitivity of 28% in 39 HER2-positive patients (FISH), and Mazouni et al. [29] reported a sensitivity of 56% in 16 HER2-positive patients (IHC) with a cut-off of 15 ng/ml. This is in line with our finding that the cut-off of 15 ng/ml has a low sensitivity, but high specificity in predicting the HER2 status of the primary tumor. This fact suggests that some women with HER2-negative tumors secrete detectable amounts of sHER2. However, we found no association between tumor size and sHER2 levels which was described as a parameter that might increase sHER2 levels [30, 31] . We found a positive association between nodal status and sHER2 in HER2-positive patients and between age and sHER2 in HER2-negative patients. In our patient cohort, ROC-curve analysis showed that a cutoff level of 10 ng/ml had a sensitivity of 72% and a specificity of 85% in predicting the HER2 status of the primary tumor. In contrast, Quaranta et al. [32] could not find a correlation between serum and tissue HER2 levels in an unselected patient group of 108 patients using the same cut-off as we did (10 ng/ml). In metastatic breast cancer, no clear relationship was found between baseline sHER2 levels and tumor response to trastuzumab-based treatment in a recently published metaanalysis [33] , while other groups have suggested a role of sHER2 determination [21, 34] so that no definitive conclusions can be drawn [26] . There is limited information regarding sHER2 to predict benefit from trastuzumab treatment in primary breast cancer. None of the recent adjuvant trastuzumab trials have published an analysis of sHER2 [35] . The rationale of determining sHER2 with no primary tumor present seems weak. In our randomized NTtrial, we could show in a relatively large number of patients that elevated sHER2 levels above 15 ng/ml as well as a decrease of sHER2 levels of more than 20% from the beginning of NT to the end of NT was associated with pCR in HER2-positive patients. This effect was observed in univariate and multivariate analysis. Two smaller published reports investigated the correlation between pretreatment sHER2 and pathologic complete response during NT plus trastuzumab. Köstler et al. evaluated sHER2 levels in a trastuzumab-based neoadjuvant setting in 16 patients. In this small group of patients, they could show that a decrease of sHER2 levels was associated with response to therapy [28] . In 39 patients with NT-treatment, 29 patients receiving a trastuzumab combination, Mazouni et al. [29] could only find a role of decreasing sHER2 levels in predicting therapy response from weeks 3 to 6 after therapy initiation.
In our patient group, sHER2 levels were higher in HER2-positive patients than in HER2-negative patients before initiation of chemotherapy and also after finalization of chemotherapy. The fact that sHER2 levels were not associated with tumor size supports the hypothesis that secretion of HER2 is dependent on biologic mechanisms like active shedding. One potential drawback of our study is the fact that we have no sHER2 determination after surgery since the ethics approval did not allow blood sampling at this time point. Therefore, we are not able to determine if sHER2 after chemotherapy was secreted only by the primary tumor. Also, previously published studies in patients with metastatic breast cancer have reported potential benefits of more dense serum HER2 monitoring and therefore, earlier determination of serum HER2 would have been of interest [33] . Differences between the HER2-positive and HER2-negative patient cohort concerning pCR and estrogen receptor status in our patient group are representative of the whole study population. Also in other patient cohorts, a positive HER2 status of the primary tumor was associated with negative hormone receptor status, and pCR rates were higher in patients receiving trastuzumab treatment [16, 36] . Therefore, it seems unlikely that the differences between the two cohorts are based on a selection bias.
About 49 percent of HER2-positive patients and only 14% of HER2-negative patients had a decline of sHER2 levels of more than 20% during chemotherapy. It was described that shedding of the HER2 ECD was inhibited by trastuzumab [10] . In the HER2-positive patient cohort, median prechemotherapy sHER2 levels were significantly higher in patients with pCR than in patients without pCR, and the median decrease of sHER2 levels during therapy was also higher in patients with pCR. However, we were not able to find a specific cut-off level that was able to discriminate between patients with and without pCR. This is in concordance with findings in the metastatic setting, where the baseline level of sHER2 alone was not a predictor of response to treatment [14, 37] . Moreover, we were not able to add further information to our analysis regarding different subsets of patients. In contrast to our findings, in the series reported by Mazouni et al. [29] in the neoadjuvant setting, mean sHER2 baseline values were not different between the pCR group and the group with residual disease. In the current report, we can summarize that patients who did not have a significant decline ([20%) in sHERs levels had decreased benefit from trastuzumabbased therapy. Possible mechanisms of trastuzumab resistance include altered receptor antibody interaction, PTEN loss and enhanced Akt signaling, p27 loss, signaling through other receptors [38] .
Monitoring changes in sHER2 levels after a specific time-period after trastuzumab treatment to predict clinical response might be valuable for identifying a patient population that might benefit from additional treatment regimens with other HER2 targeted therapies. Prospective clinical trials evaluating the use of other HER-2-directed therapies (e.g., receptor antibodies, sheddase inhibitors, signal transduction inhibitors, heat shock protein inhibitors, proteasome inhibitors, anti-angiogenic agents and immunestimulatory therapies) with and without continued trastuzumab therapy are currently in development to exploit the pathway following the onset of resistance. Since the truncated receptor might not be ideally treated with trastuzumab but rather with agents targeting the intracellular region of the receptor like the tyrosine kinase inhibitor lapatinib [39] , the determination of sHER2 levels might be useful in this context. Serum samples can be easily obtained and repeated determinations can be performed. Based on these considerations, we will investigate sHER2 levels in the currently ongoing neoadjuvant GeparQuinto trial where HER2-positive patients receive either trastuzumab or lapatinib in addition to chemotherapy. Therefore, our findings form the basis for further studies which may lead to an improvement of current treatment strategies.
